Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARWR Arrowhead Pharmaceuticals	$15.75 -2.9%	$14.14	$9.57 ▼ $30.41	$2.17B	0.96	1.53 million shs	192,644 shs
BCYC Bicycle Therapeutics	$8.32 -4.3%	$8.07	$6.10 ▼ $28.67	$575.85M	1.46	388,369 shs	34,363 shs
MIRM Mirum Pharmaceuticals	$49.30 +0.6%	$43.06	$25.73 ▼ $54.23	$2.44B	0.95	509,409 shs	51,334 shs
NAMS NewAmsterdam Pharma	$20.76 -1.3%	$18.09	$14.06 ▼ $27.29	$2.33B	-0.03	674,953 shs	79,294 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARWR Arrowhead Pharmaceuticals	-3.11%	-1.46%	+6.15%	+5.60%	-37.06%
BCYC Bicycle Therapeutics	-0.80%	+2.24%	+7.15%	-10.32%	-64.49%
MIRM Mirum Pharmaceuticals	+1.16%	+9.79%	+8.28%	+10.70%	+81.56%
NAMS NewAmsterdam Pharma	+2.59%	+7.79%	+12.16%	-10.01%	+6.21%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARWR Arrowhead Pharmaceuticals	3.6507 of 5 stars	3.4	1.0	3.4	2.8	2.5	0.0
BCYC Bicycle Therapeutics	3.3688 of 5 stars	4.4	1.0	0.0	2.0	4.2	0.6
MIRM Mirum Pharmaceuticals	3.8704 of 5 stars	3.6	1.0	4.2	2.1	1.7	0.6
NAMS NewAmsterdam Pharma	3.0027 of 5 stars	3.5	2.0	0.0	2.6	5.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARWR Arrowhead Pharmaceuticals	2.75	Moderate Buy	$43.71	177.64% Upside
BCYC Bicycle Therapeutics	2.70	Moderate Buy	$25.00	200.66% Upside
MIRM Mirum Pharmaceuticals	3.17	Buy	$60.73	23.19% Upside
NAMS NewAmsterdam Pharma	3.00	Buy	$43.00	107.18% Upside

Current Analyst Ratings Breakdown

Latest BCYC, MIRM, ARWR, and NAMS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/12/2025	NAMS NewAmsterdam Pharma	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00
6/10/2025	NAMS NewAmsterdam Pharma	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$44.00
6/4/2025	NAMS NewAmsterdam Pharma	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$42.00
5/20/2025	ARWR Arrowhead Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
5/19/2025	MIRM Mirum Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy	$73.00
5/13/2025	MIRM Mirum Pharmaceuticals	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Strong-Buy ➝ Strong-Buy
5/13/2025	ARWR Arrowhead Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$21.00 ➝ $17.00
5/13/2025	ARWR Arrowhead Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00 ➝ $60.00
5/13/2025	MIRM Mirum Pharmaceuticals	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Strong-Buy ➝ Strong-Buy	$73.00 ➝ $77.00
5/9/2025	MIRM Mirum Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$74.00 ➝ $76.00
5/8/2025	NAMS NewAmsterdam Pharma	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$42.00 ➝ $40.00

(Data available from 6/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARWR Arrowhead Pharmaceuticals	$545.21M	3.99	N/A	N/A	$1.54 per share	10.22
BCYC Bicycle Therapeutics	$25.72M	22.39	N/A	N/A	$12.35 per share	0.67
MIRM Mirum Pharmaceuticals	$379.25M	6.44	N/A	N/A	$5.33 per share	9.25
NAMS NewAmsterdam Pharma	$47.14M	49.43	N/A	N/A	$3.50 per share	5.93

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARWR Arrowhead Pharmaceuticals	-$599.49M	-$1.40	N/A	N/A	N/A	N/A	-236.60%	-64.09%	8/6/2025 (Estimated)
BCYC Bicycle Therapeutics	-$180.66M	-$3.14	N/A	N/A	N/A	-450.64%	-27.35%	-20.81%	8/5/2025 (Estimated)
MIRM Mirum Pharmaceuticals	-$163.41M	-$1.61	N/A	N/A	N/A	-31.69%	-41.22%	-14.81%	8/6/2025 (Estimated)
NAMS NewAmsterdam Pharma	-$176.94M	-$1.88	N/A	N/A	N/A	N/A	N/A	N/A	8/6/2025 (Estimated)

Latest BCYC, MIRM, ARWR, and NAMS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	MIRM Mirum Pharmaceuticals	-$0.35	-$0.30	+$0.05	-$0.30	$98.47 million	$111.59 million
5/12/2025	Q2 2025	ARWR Arrowhead Pharmaceuticals	-$0.06	$2.75	+$2.81	$2.75	$116.27 million	$542.71 million
5/8/2025	Q1 2025	NAMS NewAmsterdam Pharma	-$0.45	-$0.49	-$0.04	-$0.34	$1.46 million	$2.98 million
5/1/2025	Q1 2025	BCYC Bicycle Therapeutics	-$0.86	-$0.88	-$0.02	-$0.88	$8.67 million	$9.98 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARWR Arrowhead Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BCYC Bicycle Therapeutics	N/A	N/A	N/A	N/A	N/A
MIRM Mirum Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NAMS NewAmsterdam Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARWR Arrowhead Pharmaceuticals	7.27	6.09	6.09
BCYC Bicycle Therapeutics	N/A	17.13	17.13
MIRM Mirum Pharmaceuticals	1.33	3.34	3.15
NAMS NewAmsterdam Pharma	N/A	10.61	10.61

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARWR Arrowhead Pharmaceuticals	62.61%
BCYC Bicycle Therapeutics	86.15%
MIRM Mirum Pharmaceuticals	N/A
NAMS NewAmsterdam Pharma	89.89%

Insider Ownership

Company	Insider Ownership
ARWR Arrowhead Pharmaceuticals	4.30%
BCYC Bicycle Therapeutics	22.90%
MIRM Mirum Pharmaceuticals	14.36%
NAMS NewAmsterdam Pharma	20.84%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARWR Arrowhead Pharmaceuticals	400	138.10 million	120.68 million	Optionable
BCYC Bicycle Therapeutics	240	69.25 million	63.18 million	Optionable
MIRM Mirum Pharmaceuticals	140	49.54 million	37.03 million	Optionable
NAMS NewAmsterdam Pharma	4	112.27 million	74.37 million	Optionable

BCYC, MIRM, ARWR, and NAMS Headlines

Recent News About These Companies

NewAmsterdam Pharma (NASDAQ:NAMS) Shares Purchased by Handelsbanken Fonder AB

June 13 at 4:34 AM | marketbeat.com

5NAMS : What Analysts Are Saying About NewAmsterdam Pharma...

June 12 at 9:56 AM | benzinga.com

Strong Buy Recommendation for NewAmsterdam Pharma Driven by Promising Cardiovascular and Alzheimer’s Opportunities

June 12 at 8:34 AM | tipranks.com

NewAmsterdam Pharma (NASDAQ:NAMS) Given Buy Rating at Needham & Company LLC

June 12 at 8:30 AM | marketbeat.com

Stifel Initiates Coverage of NewAmsterdam Pharma Company N.V. (NAMS) with Buy Recommendation

June 11 at 11:54 PM | msn.com

NewAmsterdam Pharma Company N.V. (NAMS) Initiated with a Buy at Stifel

June 11 at 9:25 PM | insidermonkey.com

NewAmsterdam Pharma Rings the Closing Bell

June 11 at 6:53 PM | nasdaq.com

NewAmsterdam Pharma (NASDAQ:NAMS) Shares Down 4.4% - Should You Sell?

June 11 at 12:56 PM | marketbeat.com

NewAmsterdam Pharma Schedules R&D Day for June 2025

June 11 at 9:43 AM | tipranks.com

NewAmsterdam Pharma (NASDAQ:NAMS) Coverage Initiated by Analysts at Stifel Nicolaus

June 11 at 3:09 AM | americanbankingnews.com

Cantor Fitzgerald Forecasts NAMS FY2026 Earnings

June 11 at 2:23 AM | americanbankingnews.com

NewAmsterdam Pharma (NASDAQ:NAMS) Trading 7.5% Higher - Should You Buy?

June 10 at 3:48 PM | marketbeat.com

Positive top-line Alzheimer’s disease data from NewAmsterdam

June 10 at 10:30 AM | thepharmaletter.com

Analysts Have Just Cut Their NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Revenue Estimates By 14%

June 10 at 10:30 AM | finance.yahoo.com

Analysts Offer Predictions for NAMS FY2026 Earnings

June 10 at 8:56 AM | marketbeat.com

NewAmsterdam Pharma (NASDAQ:NAMS) Now Covered by Stifel Nicolaus

June 10 at 8:56 AM | marketbeat.com

NewAmsterdam Pharma Shares Rise on Positive Alzheimer's Cholesterol Treatment Data

June 10 at 5:27 AM | marketwatch.com

NewAmsterdam links lipid-lowering drug to improvement in Alzheimer's cognition biomarker

June 10 at 5:27 AM | fiercebiotech.com

NewAmsterdam says cholesterol drug may also combat Alzheimer’s

June 10 at 5:27 AM | biopharmadive.com

NewAmsterdam Pharma Announces Positive Topline Alzheimer’s Disease Data from BROADWAY Clinical Trial

June 10 at 5:27 AM | finance.yahoo.com

Stifel Initiates Coverage on NewAmsterdam Pharma (NAMS) with Positive Outlook | NAMS Stock News

June 9, 2025 | gurufocus.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCYC, MIRM, ARWR, and NAMS Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

$15.74 -0.48 (-2.93%)

As of 11:09 AM Eastern

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Bicycle Therapeutics NASDAQ:BCYC

$8.32 -0.38 (-4.32%)

As of 11:08 AM Eastern

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Mirum Pharmaceuticals NASDAQ:MIRM

$49.30 +0.28 (+0.56%)

As of 11:09 AM Eastern

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.

NewAmsterdam Pharma NASDAQ:NAMS

$20.76 -0.28 (-1.31%)

As of 11:08 AM Eastern

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time